Home / Recalls / Pacifico National, Inc. Dba AmEx Pharmacy / D-1849-2019

D-1849-2019 Class II Terminated

Recalled by Pacifico National, Inc. Dba AmEx Pharmacy — Melbourne, FL

FDA drug recall D-1849-2019 was initiated by Pacifico National, Inc. Dba AmEx Pharmacy on Aug 30, 2019 and is designated Class II. Reason for recall: Lack of assurance of sterility. The recall status is terminated (terminated Oct 8, 2020).

Recall Details

Product Type: Drugs
Report Date: Sep 18, 2019
Initiation Date: Aug 30, 2019
Termination Date: Oct 8, 2020
Voluntary/Mandated: Voluntary: Firm initiated

Product Description

Bevacizumab, 2.5 mg/0.1 mL, Norm-Ject Syringe Intravitreal Injection, Single use only, Rx only, Repackaged by AmEx Pharmacy 1515 Elizabeth St. Suite J Melbourne, FL 32901

Reason for Recall

Lack of assurance of sterility.

Distribution Pattern

Continental U.S. and Puerto Rico

Code Information

All lots remaining within expiry.

Source

Dataset: openFDA drug recall enforcement reports
FDA record: This recall in openFDA (JSON)
Enforcement Report: Search FDA's Enforcement Report for D-1849-2019
openFDA file date: Oct 23, 2026
Loaded by RegDataLab: Oct 25, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Other recalls by Pacifico National, Inc. Dba AmEx Pharmacy

D-1850-2019 Class II — Bevacizumab, 1.25 mg/0.05 mL, 31G MJ Syringe Intravitreal Injection, Single use… (Aug 30, 2019)
D-1271-2019 Class II — BEVACIZUMAB 1.25 mg/0.05 mL 31G MJ syringe Intravitreal Injection. This… (Apr 19, 2019)
D-0869-2016 Class I — Avastin (Bevacizumab) 2 mg/0.08 mL syringe, Office Administration Only, AmEx… (Jan 20, 2015)
D-0870-2016 Class I — Avastin (Bevacizumab) 1.25 mg/0.05 mL syringe, Office Administration Only, AmEx… (Jan 20, 2015)